SCN2A explained

Sodium channel protein type 2 subunit alpha, also known as Nav1.2, is an ion channel protein encoded by the SCN2A gene in humans.[1] It represents one member of the sodium channel alpha subunit gene family. The SCN2A gene is located on chromosome 2 (2q24.3) in proximity to two other voltage-gated sodium channel genes, namely SCN1A and SCN9A.[2] Nav1.2 is distributed throughout the human central nervous system where it plays a major role in the initiation and propagation of action potentials. It is absent from peripheral tissues, with the exception of enteric neurons.[3] Pathologic mutations in the SCN2A gene cause a broad spectrum of neurological conditions, such as epilepsy, autism spectrum disorder (ASD), intellectual disability (ID) and/or developmental delay, called SCN2A-related disorders.[4]

Structure

The SCN2A gene is composed of 27 exons and comprises more than 150 kilobases. There are two major splice variants known, a neonatal isoform and an adult isoform, which differ in one amino acid at position 209 (Asn versus Asp). The neonatal isoform might limit neuronal excitability during development. The voltage-gated sodium channel Nav1.2 encoded by the SCN2A gene consists of 2005 amino acids. This single polypeptide forms a pseudotetrameric channel of four similar domains (I - IV) where each domain contains 6 transmembrane segments, including a voltage sensing region, a pore forming region and an ion-selectivity filter.[5] In the living organism, Nav1.2 is a transmembrane glycoprotein complex composed of a large alpha subunit (encoded by the SCN2A gene) and one or more regulatory beta subunits (encoded by SCNxB genes).[6]

Function

The principal function of Nav1.2, similar to other members of the voltage-gated sodium channel family, is to mediate sodium influx into neurons upon membrane depolarization, thereby generating and propagating action potentials across distinct neuronal subtypes.

Nav1.2 functions mainly in excitatory neurons in cortical structures similar to Nav1.6, whereas expression of Nav1.1 (encoded by the SCN1A gene) is found in mutual distinct, inhibitory neuronal classes.[7] However, the distribution of Nav1.2 changes during development. Nav1.2 channels are initially expressed at the axon initial segments (the site of action potential initiation) of excitatory pyramidal cells in both hippocampal and cortical excitatory cells. While these levels remain constant in the hippocampus, in cortical excitatory cells, Nav1.2 becomes restricted to the portion of the axon initial segment closest to the cell body and in dendrites at the age of 1–2 years in humans. Nav1.6 gradually becomes the predominant channel type at the distal axon initial segment and axonal nodes of Ranvier. In mature neurons, Nav1.2 is distributed only throughout unmyelinated axons. In contrast, its expression pattern in the cerebellum seems to persist throughout development, suggesting distinct roles for Nav1.2 in mature neurons of the neocortex and cerebellum. When Nav1.6 takes over the initiation of action potentials, Nav1.2 might play a crucial role in driving their backpropagation into dendrites. This backpropagation could impact activity-dependent processes such as synaptic maturation, plasticity, and gene transcription.

The activity of Nav1.2 is influenced by several factors, such as protein-protein interactions, posttranslational modifications (e.g. phosphorylation, pamitoylation), and changes in intracellular Ca2+ concentration.

Clinical significance

Mutations in the SCN2A gene can cause a broad spectrum of disorders collectively referred to as SCN2A-related disorders. These include cases of ASD, self-limited epilepsy, early infantile developmental and epileptic encephalopathy, later onset developmental and epileptic encephalopathy, infantile spasms, SCN2A-related disorders without epilepsy, episodic ataxia, and further movement disorders. Two major groups of SCN2A mutations can be distinguished based on their functional consequences and response to seizure medication: gain of function mutations, typically associated with seizure onset within the first three months of life, and loss of function mutations, in which seizures begin after the first three months or may never occur. The former group tends to benefit from treatment with sodium channel blockers, whereas in the latter, such treatment is often ineffective or may even exacerbate seizures.[8] Notably, SCN2A is known to be the most prominent genetic risk factor for autism-spectrum-disorders.

SCN2A gene mutations have also been identified in bitemporal glucose hypometabolism,[9] and bipolar disorder.[10] Furthermore, mutations in SCN2A have been demonstrated to impair enteric neuron migration during development, which may result in gastrointestinal dysmotility, consistent with gastric motility symptoms reported in ASD patients with underlying SCN2A mutations.

See also

Further reading

External links

Patient advocacy organizations (PAO / PAG)

Other links

Notes and References

  1. Web site: Entrez Gene: SCN2A sodium channel, voltage-gated, type II, alpha subunit .
  2. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL, Walker MF, Ober GT, Teran NA, Song Y, El-Fishawy P, Murtha RC, Choi M, Overton JD, Bjornson RD, Carriero NJ, Meyer KA, Bilguvar K, Mane SM, Sestan N, Lifton RP, Günel M, Roeder K, Geschwind DH, Devlin B, State MW . De novo mutations revealed by whole-exome sequencing are strongly associated with autism . Nature . 485 . 7397 . 237–241 . April 2012 . 22495306 . 3667984 . 10.1038/nature10945 . 2012Natur.485..237S .
  3. Web site: McCluskey . Kate E. . Stovell . Katherine M. . Law . Karen . Kostyanovskaya . Elina . Schmidt . James . Exner . Cameron R. T. . Dea . Jeanselle . Brimble . Elise . State . Matthew W. . 2024-05-29 . Autism gene variants disrupt enteric neuron migration and cause gastrointestinal dysmotility . 2026-02-15 . doi.org.
  4. Book: George Jr AL . Abbott M, Bender KJ, Brunklaus A, Demarest S, Egan S, Haviland I, Kearney JA, Myers LS, Olson HE, Sanders SJ . SCN2A-related disorders . Cambridge, United Kingdom New York, NY . 2024 . Cambridge University Press . 978-1-009-53036-1 . Cambridge elements. Elements in genetics in epilepsy .
  5. de Lera Ruiz M, Kraus RL . Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications . Journal of Medicinal Chemistry . 58 . 18 . 7093–7118 . September 2015 . 25927480 . 10.1021/jm501981g .
  6. Leterrier C, Brachet A, Fache MP, Dargent B . Voltage-gated sodium channel organization in neurons: protein interactions and trafficking pathways . Neuroscience Letters . 486 . 2 . 92–100 . December 2010 . 20817077 . 10.1016/j.neulet.2010.08.079 . Proteomics of Voltage-Gated Ion Channels .
  7. Catterall WA, Kalume F, Oakley JC . NaV1.1 channels and epilepsy . The Journal of Physiology . 588 . Pt 11 . 1849–1859 . June 2010 . 20194124 . 2901973 . 10.1113/jphysiol.2010.187484 .
  8. Wolff M, Johannesen KM, Hedrich UB, Masnada S, Rubboli G, Gardella E, Lesca G, Ville D, Milh M, Villard L, Afenjar A, Chantot-Bastaraud S, Mignot C, Lardennois C, Nava C, Schwarz N, Gérard M, Perrin L, Doummar D, Auvin S, Miranda MJ, Hempel M, Brilstra E, Knoers N, Verbeek N, van Kempen M, Braun KP, Mancini G, Biskup S, Hörtnagel K, Döcker M, Bast T, Loddenkemper T, Wong-Kisiel L, Baumeister FM, Fazeli W, Striano P, Dilena R, Fontana E, Zara F, Kurlemann G, Klepper J, Thoene JG, Arndt DH, Deconinck N, Schmitt-Mechelke T, Maier O, Muhle H, Wical B, Finetti C, Brückner R, Pietz J, Golla G, Jillella D, Linnet KM, Charles P, Moog U, Õiglane-Shlik E, Mantovani JF, Park K, Deprez M, Lederer D, Mary S, Scalais E, Selim L, Van Coster R, Lagae L, Nikanorova M, Hjalgrim H, Korenke GC, Trivisano M, Specchio N, Ceulemans B, Dorn T, Helbig KL, Hardies K, Stamberger H, de Jonghe P, Weckhuysen S, Lemke JR, Krägeloh-Mann I, Helbig I, Kluger G, Lerche H, Møller RS . Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders . Brain . 140 . 5 . 1316–1336 . May 2017 . 28379373 . 10.1093/brain/awx054 . free . 1765/100043 .
  9. Sundaram SK, Chugani HT, Tiwari VN, Huq AH . SCN2A mutation is associated with infantile spasms and bitemporal glucose hypometabolism . Pediatric Neurology . 49 . 1 . 46–49 . July 2013 . 23827426 . 3868437 . 10.1016/j.pediatrneurol.2013.03.002 .
  10. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang Y, Coleman JR, Gaspar HA, de Leeuw CA, Steinberg S, Pavlides JM, Trzaskowski M, Byrne EM, Pers TH, Holmans PA, Richards AL, Abbott L, Agerbo E, Akil H, Albani D, Alliey-Rodriguez N, Als TD, Anjorin A, Antilla V, Awasthi S, Badner JA, Bækvad-Hansen M, Barchas JD, Bass N, Bauer M, Belliveau R, Bergen SE, Pedersen CB, Bøen E, Boks MP, Boocock J, Budde M, Bunney W, Burmeister M, Bybjerg-Grauholm J, Byerley W, Casas M, Cerrato F, Cervantes P, Chambert K, Charney AW, Chen D, Churchhouse C, Clarke TK, Coryell W, Craig DW, Cruceanu C, Curtis D, Czerski PM, Dale AM, de Jong S, Degenhardt F, Del-Favero J, DePaulo JR, Djurovic S, Dobbyn AL, Dumont A, Elvsåshagen T, Escott-Price V, Fan CC, Fischer SB, Flickinger M, Foroud TM, Forty L, Frank J, Fraser C, Freimer NB, Frisén L, Gade K, Gage D, Garnham J, Giambartolomei C, Pedersen MG, Goldstein J, Gordon SD, Gordon-Smith K, Green EK, Green MJ, Greenwood TA, Grove J, Guan W, Guzman-Parra J, Hamshere ML, Hautzinger M, Heilbronner U, Herms S, Hipolito M, Hoffmann P, Holland D, Huckins L, Jamain S, Johnson JS, Juréus A, Kandaswamy R, Karlsson R, Kennedy JL, Kittel-Schneider S, Knowles JA, Kogevinas M, Koller AC, Kupka R, Lavebratt C, Lawrence J, Lawson WB, Leber M, Lee PH, Levy SE, Li JZ, Liu C, Lucae S, Maaser A, MacIntyre DJ, Mahon PB, Maier W, Martinsson L, McCarroll S, McGuffin P, McInnis MG, McKay JD, Medeiros H, Medland SE, Meng F, Milani L, Montgomery GW, Morris DW, Mühleisen TW, Mullins N, Nguyen H, Nievergelt CM, Adolfsson AN, Nwulia EA, O'Donovan C, Loohuis LM, Ori AP, Oruc L, Ösby U, Perlis RH, Perry A, Pfennig A, Potash JB, Purcell SM, Regeer EJ, Reif A, Reinbold CS, Rice JP, Rivas F, Rivera M, Roussos P, Ruderfer DM, Ryu E, Sánchez-Mora C, Schatzberg AF, Scheftner WA, Schork NJ, Shannon Weickert C, Shehktman T, Shilling PD, Sigurdsson E, Slaney C, Smeland OB, Sobell JL, Søholm Hansen C, Spijker AT, St Clair D, Steffens M, Strauss JS, Streit F, Strohmaier J, Szelinger S, Thompson RC, Thorgeirsson TE, Treutlein J, Vedder H, Wang W, Watson SJ, Weickert TW, Witt SH, Xi S, Xu W, Young AH, Zandi P, Zhang P, Zöllner S, Adolfsson R, Agartz I, Alda M, Backlund L, Baune BT, Bellivier F, Berrettini WH, Biernacka JM, Blackwood DH, Boehnke M, Børglum AD, Corvin A, Craddock N, Daly MJ, Dannlowski U, Esko T, Etain B, Frye M, Fullerton JM, Gershon ES, Gill M, Goes F, Grigoroiu-Serbanescu M, Hauser J, Hougaard DM, Hultman CM, Jones I, Jones LA, Kahn RS, Kirov G, Landén M, Leboyer M, Lewis CM, Li QS, Lissowska J, Martin NG, Mayoral F, McElroy SL, McIntosh AM, McMahon FJ, Melle I, Metspalu A, Mitchell PB, Morken G, Mors O, Mortensen PB, Müller-Myhsok B, Myers RM, Neale BM, Nimgaonkar V, Nordentoft M, Nöthen MM, O'Donovan MC, Oedegaard KJ, Owen MJ, Paciga SA, Pato C, Pato MT, Posthuma D, Ramos-Quiroga JA, Ribasés M, Rietschel M, Rouleau GA, Schalling M, Schofield PR, Schulze TG, Serretti A, Smoller JW, Stefansson H, Stefansson K, Stordal E, Sullivan PF, Turecki G, Vaaler AE, Vieta E, Vincent JB, Werge T, Nurnberger JI, Wray NR, Di Florio A, Edenberg HJ, Cichon S, Ophoff RA, Scott LJ, Andreassen OA, Kelsoe J, Sklar P . Genome-wide association study identifies 30 loci associated with bipolar disorder . Nature Genetics . 51 . 5 . 793–803 . May 2019 . 31043756 . 6956732 . 10.1038/s41588-019-0397-8 .
  11. Web site: ICD-10-CM/PCS MS-DRG v43.0 Definitions Manual . October 15, 2025 . Centers for Medicaid and Medicare Services .